Insider Trading History of Collins Helen Louise

The following table details the insider trading activities (stock purchases, stock sales, and stock option exercises) of Collins Helen Louise since 2020. This trader's CIK number is 1701247. At the time of last reporting, Collins Helen Louise was the CHIEF MEDICAL OFFICER of Enliven Therapeutics, Inc.. (stock ticker symbol ELVN). Also see all insider trading activities at Enliven Therapeutics, Inc..

Note that in the past Collins Helen Louise also reported insider trading activities as an insider of the following companies:

Yearly summary of insider trading at Enliven Therapeutics, Inc. (ELVN) by Collins Helen Louise

Insider Buying Insider Sales Option Exercises
Year Symbol Shares Value Shares Value Shares Value
2024 ELVN 0 $0 20,816 $525,962 20,816 $51,623

Yearly summary of insider trading at Five Prime Therapeutics, Inc. (FPRX) by Collins Helen Louise

Insider Buying Insider Sales Option Exercises
Year Symbol Shares Value Shares Value Shares Value
2020 FPRX 0 $0 0 $0 44,000 $0


Insider trading activities at 2 companies by Collins Helen Louise:

1. Enliven Therapeutics, Inc. (ELVN)

2. Five Prime Therapeutics, Inc. (FPRX)

Table 1. Insider trading of Enliven Therapeutics, Inc. (ELVN) by Collins Helen Louise

Trade Date Symbol Trade Type Shares Price ($) Value ($)
2024-10-18 ELVN Sale 816 30.00 24,482
2024-10-18 ELVN Option Ex 816 2.48 2,023
2024-04-11 ELVN Sale 20,000 25.07 501,480
2024-04-11 ELVN Option Ex 20,000 2.48 49,600

Table 2. Insider trading of Five Prime Therapeutics, Inc. (FPRX) by Collins Helen Louise

Trade Date Symbol Trade Type Shares Price ($) Value ($)
2020-12-11 FPRX Option Ex 22,000 .00 0
2020-11-11 FPRX Option Ex 22,000 .00 0

Insider trading activities including stock purchases, stock sales, and option exercises listed in the above table cannot be completely guaranteed as to their accuracy. For more information regarding the trades made by Collins Helen Louise (CHIEF MEDICAL OFFICER of Enliven Therapeutics, Inc. at the time of this reporting) see the Securities and Exchange Commission (SEC) website.



©2023, insider-monitor.com. All rights reserved.